Flash FinanceUS
Pre-market S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · Integra Lifesciences (IART)

Integra LifeSciences Q1 revenue rises 3.7%, but cuts 2025 adjusted EPS guidance

Negative Impact 4 of 5 earnings Written later

Integra LifeSciences reported first-quarter 2025 results on May 5, 2025. Reported revenue rose 3.7% to $382.7 million, but organic revenue fell 3.5%, the GAAP net loss widened to $25.3 million, and adjusted earnings per diluted share fell to $0.41 from $0.55. The company reaffirmed its full-year revenue guidance but cut its full-year adjusted EPS guidance to $2.19 to $2.29, including an estimated $(0.22) per share impact from new tariffs.

Key points

  • Q1 revenue was $382.7 million, up 3.7% on a reported basis and down 3.5% on an organic basis.
  • GAAP net loss was $25.3 million, or $(0.33) per diluted share, versus a $3.3 million loss, or $(0.04), a year earlier.
  • Adjusted EPS was $0.41 versus $0.55; full-year adjusted EPS guidance was cut to $2.19 to $2.29.
  • Full-year 2025 revenue guidance of $1.650 billion to $1.715 billion was reaffirmed; second-quarter adjusted EPS is expected at $0.40 to $0.45.

The filing

CompanyIntegra Lifesciences (IART)
Form8-K, current report
Filed with the SECMay 5, 2025, 6:45 AM ET
Accession number0000917520-25-000038

Items reported: 2.02 Results of Operations

Read the filing on SEC.gov ↗

Written by AI on Nov 8, 2026, 6:59 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on May 05, 2025.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.